The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
zu einem DPD-Mangel führen, der mit Risiken für eine besonders hohe 5-FU-Toxizität einhergeht. Aus diesem Grund rät die Europäische Arzneimittel-Agentur (EMA) inzwischen zu einer ...
a prodrug of 5-FU. The DPYD gene encodes the enzyme DPD, which breaks down >80% of fluorouracil. Patients with certain homozygous or compound heterozygous variants in the DPYD gene, known to result in ...
Sie haben dennoch Zugriff auf den ungekürzten Text, sofern Sie über einen kostenfreien lifePR-Leser-Zugang verfügen.
and 5-fluorouracil (5-FU). Certain variants in the DPYD gene lead to decreased production of the enzyme DPD, a protein needed to break down fluoropyrimidines. Patients with these genetic variants are ...
Overall, the majority of studies observe a significant association between genetic variants in DPYD and severe 5-FU-related toxicities. While this general finding seems to be reproducible across a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback